ClinicalTrials.gg

Program

BFF MDI

Its studies are mostly in Asthma, led by AstraZeneca.

Furthest: phase 3, since Nov 6, 20262 company-led studies, 2 open or runningNext primary completion: May 23, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca22 open or runningphase 3since Nov 6, 2026Apr 7, 2026May 23, 2029phase 2 · NCT07525375

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 7, 2026First study: phase 2 study in AsthmaFirst studyNCT07525375 · 69 planned · United States, Argentina, Czechia and more
  2. Nov 6, 2026Phase 3 study in AsthmaPhase 3 reachedNCT07934420 · 216 planned

Ahead

  1. May 23, 2029Primary completion: phase 2 study in AsthmaNCT07525375
  2. Jul 30, 2029Primary completion: phase 3 study in AsthmaNCT07934420

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07934420Asthma3Not yet recruitingJul 30, 2029216
NCT07525375Asthma · United States, Argentina, Czechia and more2RecruitingMay 23, 202969

How it is read

Names in the registry

  • “BFF MDI”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.